Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease
December 20, 2017 09:02 ET
|
Amarantus Bioscience Holdings, Inc.
Issued claims include therapeutic protein, gene therapy and cell therapy applicationsPatent extends MANF Therapeutics' exclusivity for MANF treatment of Parkinson's disease in Japan into 2029 SAN...
Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF
December 14, 2017 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
Data demonstrates MANF's role in modulating the immune microenvironment in the retina and its potential for treating retinal disordersPatent extends MANF Therapeutics' exclusivity for MANF and CDNF...
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
December 11, 2017 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
Allowed claims include the treatment of Type 1 and Type 2 DiabetesOnce issued, patents extend exclusivity for MANF in the US into 2032 SAN FRANCISCO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Amarantus...
Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID
December 08, 2017 10:27 ET
|
Amarantus Bioscience Holdings, Inc.
Patents extend Eltoprazine Parkinson’s disease LID treatment exclusivity into 2033 SAN FRANCISCO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based...
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer's Disease and Parkinson's disease with Eltoprazine
December 05, 2017 07:45 ET
|
Amarantus Bioscience Holdings, Inc.
SAN FRANCISCO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class...
Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference
November 13, 2015 08:30 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Announces Issuance of Australian Patent No. 61/057,713 Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease
October 29, 2015 09:58 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs
October 26, 2015 08:30 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO, Oct. 26, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Submits Orphan Drug Designation Application to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia
October 22, 2015 09:15 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus to Present at BIO Investor Forum 2015
October 19, 2015 08:00 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...